Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade

T. Cantaert, L. De Rycke, C. P. Mavragani, C. A. Wijbrandts, T. B. Niewold, T. Niers, B. Vandooren, E. M. Veys, D. Richel, P. P. Tak, M. K. Crow, D. Baeten

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: Type I interferons and apoptotic particles contribute to antinuclear autoimmunity in experimental models. This study assessed whether similar mechanisms contribute to break peripheral B-cell tolerance in humans by studying the induction of antinuclear antibodies by tumour necrosis factor blockade in spondyloarthritis. Methods: 40 spondyloarthritis patients treated with infliximab or etanercept and 20 renal cell carcinoma patients treated with sorafenib were studied. Serum antinucleosome IgM and nucleosomes were measured by ELISA. Type I interferon serum activity was measured using a functional reporter cell assay. Synovial apoptosis was assessed by terminal transferase nick end-labelling (TUNEL) assay and anti-active caspase-3 immunostaining. Complement was measured by nephelometry. Results: Despite a similar clinical improvement and reduction of synovial inflammation, antinucleosome IgM were induced by infliximab but not etanercept. This induction did not correlate with type I interferon activity, which was transiently downmodulated by infliximab but persistently upregulated by etanercept. In contrast, antinucleosome IgM levels did correlate with serum nucleosome levels, which were significantly upregulated by infliximab but not by etanercept treatment. This increase in serum nucleosome levels was not directly related to massive cell death, but rather to a decrease of complement 3 and 4 serum levels during infliximab treatment. Conclusion: Infliximab and etanercept have a differential effect on both type I interferon activity and nucleosome levels. Only elevated serum nucleosomes relate to the induction of antinucleosome antibodies after infliximab treatment.

Original languageEnglish (US)
Pages (from-to)1022-1029
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume68
Issue number6
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

Nuclear Antigens
Autoimmunity
Nucleosomes
Tumor Necrosis Factor-alpha
Interferon Type I
Serum
Immunoglobulin M
Assays
Cells
Nephelometry and Turbidimetry
Complement C4
Complement C3
Antinuclear Antibodies
In Situ Nick-End Labeling
Cell death
Transferases
Infliximab
Renal Cell Carcinoma
Caspase 3
Labeling

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Cantaert, T., De Rycke, L., Mavragani, C. P., Wijbrandts, C. A., Niewold, T. B., Niers, T., ... Baeten, D. (2009). Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. Annals of the Rheumatic Diseases, 68(6), 1022-1029. https://doi.org/10.1136/ard.2008.093724

Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. / Cantaert, T.; De Rycke, L.; Mavragani, C. P.; Wijbrandts, C. A.; Niewold, T. B.; Niers, T.; Vandooren, B.; Veys, E. M.; Richel, D.; Tak, P. P.; Crow, M. K.; Baeten, D.

In: Annals of the Rheumatic Diseases, Vol. 68, No. 6, 06.2009, p. 1022-1029.

Research output: Contribution to journalArticle

Cantaert, T, De Rycke, L, Mavragani, CP, Wijbrandts, CA, Niewold, TB, Niers, T, Vandooren, B, Veys, EM, Richel, D, Tak, PP, Crow, MK & Baeten, D 2009, 'Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade', Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 1022-1029. https://doi.org/10.1136/ard.2008.093724
Cantaert, T. ; De Rycke, L. ; Mavragani, C. P. ; Wijbrandts, C. A. ; Niewold, T. B. ; Niers, T. ; Vandooren, B. ; Veys, E. M. ; Richel, D. ; Tak, P. P. ; Crow, M. K. ; Baeten, D. / Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade. In: Annals of the Rheumatic Diseases. 2009 ; Vol. 68, No. 6. pp. 1022-1029.
@article{f94442bb27fa4eeb8861ae38a53c4a99,
title = "Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade",
abstract = "Objective: Type I interferons and apoptotic particles contribute to antinuclear autoimmunity in experimental models. This study assessed whether similar mechanisms contribute to break peripheral B-cell tolerance in humans by studying the induction of antinuclear antibodies by tumour necrosis factor blockade in spondyloarthritis. Methods: 40 spondyloarthritis patients treated with infliximab or etanercept and 20 renal cell carcinoma patients treated with sorafenib were studied. Serum antinucleosome IgM and nucleosomes were measured by ELISA. Type I interferon serum activity was measured using a functional reporter cell assay. Synovial apoptosis was assessed by terminal transferase nick end-labelling (TUNEL) assay and anti-active caspase-3 immunostaining. Complement was measured by nephelometry. Results: Despite a similar clinical improvement and reduction of synovial inflammation, antinucleosome IgM were induced by infliximab but not etanercept. This induction did not correlate with type I interferon activity, which was transiently downmodulated by infliximab but persistently upregulated by etanercept. In contrast, antinucleosome IgM levels did correlate with serum nucleosome levels, which were significantly upregulated by infliximab but not by etanercept treatment. This increase in serum nucleosome levels was not directly related to massive cell death, but rather to a decrease of complement 3 and 4 serum levels during infliximab treatment. Conclusion: Infliximab and etanercept have a differential effect on both type I interferon activity and nucleosome levels. Only elevated serum nucleosomes relate to the induction of antinucleosome antibodies after infliximab treatment.",
author = "T. Cantaert and {De Rycke}, L. and Mavragani, {C. P.} and Wijbrandts, {C. A.} and Niewold, {T. B.} and T. Niers and B. Vandooren and Veys, {E. M.} and D. Richel and Tak, {P. P.} and Crow, {M. K.} and D. Baeten",
year = "2009",
month = "6",
doi = "10.1136/ard.2008.093724",
language = "English (US)",
volume = "68",
pages = "1022--1029",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade

AU - Cantaert, T.

AU - De Rycke, L.

AU - Mavragani, C. P.

AU - Wijbrandts, C. A.

AU - Niewold, T. B.

AU - Niers, T.

AU - Vandooren, B.

AU - Veys, E. M.

AU - Richel, D.

AU - Tak, P. P.

AU - Crow, M. K.

AU - Baeten, D.

PY - 2009/6

Y1 - 2009/6

N2 - Objective: Type I interferons and apoptotic particles contribute to antinuclear autoimmunity in experimental models. This study assessed whether similar mechanisms contribute to break peripheral B-cell tolerance in humans by studying the induction of antinuclear antibodies by tumour necrosis factor blockade in spondyloarthritis. Methods: 40 spondyloarthritis patients treated with infliximab or etanercept and 20 renal cell carcinoma patients treated with sorafenib were studied. Serum antinucleosome IgM and nucleosomes were measured by ELISA. Type I interferon serum activity was measured using a functional reporter cell assay. Synovial apoptosis was assessed by terminal transferase nick end-labelling (TUNEL) assay and anti-active caspase-3 immunostaining. Complement was measured by nephelometry. Results: Despite a similar clinical improvement and reduction of synovial inflammation, antinucleosome IgM were induced by infliximab but not etanercept. This induction did not correlate with type I interferon activity, which was transiently downmodulated by infliximab but persistently upregulated by etanercept. In contrast, antinucleosome IgM levels did correlate with serum nucleosome levels, which were significantly upregulated by infliximab but not by etanercept treatment. This increase in serum nucleosome levels was not directly related to massive cell death, but rather to a decrease of complement 3 and 4 serum levels during infliximab treatment. Conclusion: Infliximab and etanercept have a differential effect on both type I interferon activity and nucleosome levels. Only elevated serum nucleosomes relate to the induction of antinucleosome antibodies after infliximab treatment.

AB - Objective: Type I interferons and apoptotic particles contribute to antinuclear autoimmunity in experimental models. This study assessed whether similar mechanisms contribute to break peripheral B-cell tolerance in humans by studying the induction of antinuclear antibodies by tumour necrosis factor blockade in spondyloarthritis. Methods: 40 spondyloarthritis patients treated with infliximab or etanercept and 20 renal cell carcinoma patients treated with sorafenib were studied. Serum antinucleosome IgM and nucleosomes were measured by ELISA. Type I interferon serum activity was measured using a functional reporter cell assay. Synovial apoptosis was assessed by terminal transferase nick end-labelling (TUNEL) assay and anti-active caspase-3 immunostaining. Complement was measured by nephelometry. Results: Despite a similar clinical improvement and reduction of synovial inflammation, antinucleosome IgM were induced by infliximab but not etanercept. This induction did not correlate with type I interferon activity, which was transiently downmodulated by infliximab but persistently upregulated by etanercept. In contrast, antinucleosome IgM levels did correlate with serum nucleosome levels, which were significantly upregulated by infliximab but not by etanercept treatment. This increase in serum nucleosome levels was not directly related to massive cell death, but rather to a decrease of complement 3 and 4 serum levels during infliximab treatment. Conclusion: Infliximab and etanercept have a differential effect on both type I interferon activity and nucleosome levels. Only elevated serum nucleosomes relate to the induction of antinucleosome antibodies after infliximab treatment.

UR - http://www.scopus.com/inward/record.url?scp=67449164836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449164836&partnerID=8YFLogxK

U2 - 10.1136/ard.2008.093724

DO - 10.1136/ard.2008.093724

M3 - Article

C2 - 18625621

AN - SCOPUS:67449164836

VL - 68

SP - 1022

EP - 1029

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -